Stockholm - Delayed Quote SEK

Sprint Bioscience AB (publ) (SPRINT.ST)

Compare
1.5660 -0.0560 (-3.45%)
At close: December 13 at 4:22:29 PM GMT+1
Loading Chart for SPRINT.ST
DELL
  • Previous Close 1.6220
  • Open 1.5800
  • Bid 1.5360 x --
  • Ask 1.5760 x --
  • Day's Range 1.5340 - 1.5900
  • 52 Week Range 0.7560 - 2.2500
  • Volume 13,154
  • Avg. Volume 95,817
  • Market Cap (intraday) 109.338M
  • Beta (5Y Monthly) 0.36
  • PE Ratio (TTM) --
  • EPS (TTM) -0.2800
  • Earnings Date Feb 12, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 3.00

Sprint Bioscience AB (publ), a pharmaceutical company, engages in the development of pharmaceutical products in the areas of cancer in Sweden. It develops VPS34, a drug candidate for the treatment of various types of cancer by using immunotherapies; and PETRA01, a drug candidate for the treatment of cancer. The company also focuses on research of products for the treatment of tumor metabolism, nash, and diabetes. Sprint Bioscience AB (publ) was incorporated in 2009 and is based in Huddinge, Sweden.

www.sprintbioscience.com

36

Full Time Employees

December 31

Fiscal Year Ends

Recent News: SPRINT.ST

View More

Performance Overview: SPRINT.ST

Trailing total returns as of 12/13/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

SPRINT.ST
9.74%
OMX Stockholm 30 Index
6.60%

1-Year Return

SPRINT.ST
12.76%
OMX Stockholm 30 Index
9.49%

3-Year Return

SPRINT.ST
61.18%
OMX Stockholm 30 Index
10.39%

5-Year Return

SPRINT.ST
81.59%
OMX Stockholm 30 Index
45.39%

Compare To: SPRINT.ST

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: SPRINT.ST

View More

Valuation Measures

Annual
As of 12/13/2024
  • Market Cap

    109.34M

  • Enterprise Value

    77.62M

  • Trailing P/E

    5.84

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.81

  • Price/Book (mrq)

    8.11

  • Enterprise Value/Revenue

    1.29

  • Enterprise Value/EBITDA

    3.40

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -31.10%

  • Return on Assets (ttm)

    -20.45%

  • Return on Equity (ttm)

    -82.55%

  • Revenue (ttm)

    61.45M

  • Net Income Avi to Common (ttm)

    -19.11M

  • Diluted EPS (ttm)

    -0.2800

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    31.72M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -15.43M

Research Analysis: SPRINT.ST

View More

Company Insights: SPRINT.ST

Research Reports: SPRINT.ST

View More

People Also Watch

Waiting for permission
Allow microphone access to enable voice search

Try again.